Introduction
The decline in circulating estrogen during menopause results in structural changes, including thinning of the vaginal epithelium and atrophy of the vulva, vagina, and urinary tract. 1 Vulvovaginal atrophy (VVA)-also known as atrophic vaginitis-is a common condition that affects up to 60% of postmenopausal women. 2, 3 It may present symptoms of vaginal dryness, burning, itching, irritation, and dyspareunia.
These symptoms usually do not resolve naturally, or may even worsen, without effective treatments. In severe cases of VVA, patients may seek for surgical intervention. 4 Although non-hormonal therapy, including over-thecounter lubricants and moisturizers, may help relieve symptoms of VVA, it does not treat the underlying condition. 5 Black cohosh combined with St. John' s wort was effective for eliminating symptom of hot flash, but did not show an estrogenic effect on VVA. 6, 7 Local estrogen therapy, such as estrogen creams, suppositories, and rings, are the treatment of choice for women with VVA who do not have any other postmenopausal symptoms. These may improve symptoms and restore vaginal anatomy. 8 However, many women consider local agents inconvenient. Systemic 
Chemical Structure and Mechanism of Action
Ospemifene is a triphenylethylene, with a similar structure to tamoxifen and toremifene (Fig. 1) The protective effect of ospemifene against breast cancer was demonstrated in preclinical studies. In an in situ mouse model, the cell proliferation was reduced significantly in ductal carcinoma when ospemifene was used. 17 Ospemifene inhibits the appearance of dimethylbenzanthracene (DMBA)-induced mammary tumors and ER-dependent MCF-7 breast cancer cells, whereas no effect was found on ER-independent MDA-MB-231 cells. 18, 19 The inhibitory effect was dosedependent. 11 When ospemifene was administered in three different doses (1 mg/kg, 10 mg/kg, and 50 mg/kg) to rats, the growth of tumors was 88%, 41%, and 21%, respectively, compared with 100% in the untreated group. The inhibitory effect was comparable with the effect of tamoxifen.
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The changes in the lipid profile was investigated in a pilot study in rhesus macaques using varying dose of ospemi-
fene. An initial weekly oral dose of 35 mg/kg of ospemifene was administered for 3 weeks. Although there was a trend toward reduced total and low-density lipoproteins (LDL) cholesterol and increased triglycerides, the difference was statistically not significant. A different dose of 60 mg/day were administered for nine weeks, followed by 12 mg/day for 3 more weeks. Although the number of subjects were too small to make a statistical comparison, there was a trend towards lowering LDL and total cholesterol. improved, and the vaginal pH level was significantly decreased. 27 Recently, a combined analysis of two phase III trials 21, 24 was published, and reported improvement in dyspareunia and vaginal dryness in three-quarters of women compared with 50% to 60% who received the placebo. 28 Ospemifene has recently been approved by the European Medicines Agency (EMA) to treat moderate-to-severe VVA in postmenopausal women who are not subject to local vaginal estrogen therapy.
Effects on BMD
Preclinical animal studies showed that ospemifene restored bone loss induced by ovariectomy. The effective dose for ospemifene to exhibit an estrogen agonist action on the bone in the two studies was 1 and 10 ng/kg, respectively.
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In a phase II clinical study, ospemifene decreased bone resorption, as seen in significant dose-dependent decreases in N-terminal cross-linking telopeptide of type 1 collagen.
Dose-dependent decreases in the markers of bone formation were also observed, as reflected in significant decreased levels of procollagen types 1C and 1N properties. Bone-specific alkaline phosphatase was also significantly reduced. These changes were similar to those seen in hormone-replacement treatments and with raloxifene. In a second double-blind phase II study, with parallel group randomization, ospemi-J MM fene and raloxifene were found to produce similar changes in markers of bone resorption and bone formation. These preclinical and clinical studies have all shown that ospemifene has an estrogenic effect on the bone, confirming a comparable bone-restoring activity between ospemifene and raloxifene.
Safety

Effects on breast
The extensive in vitro and in vivo animal models demonstrated that the cytotoxicity of ospemifene was markedly less than that of tamoxifen or raloxifene. From these studies, it was concluded that ospemifene acts as an estrogen antagonist in animal models of breast cancer. Moreover, ospemifene is only active when ERα is expressed, but not when only ERβ is present. In clinical trials with postmenopausal women, ospemifene had no adverse effects on the breast, and mammograms performed after 52 weeks of ospemifene were normal in all subjects of all groups. However, the Endocrine Society recommended against the use of ospemifene in their recent clinical practice guideline. 30 
Effects on uterus and endometrium
No cases of endometrial carcinoma have been reported.
In a phase II trial, endometrial cell proliferation was not observed, as evaluated by stable Ki-67 markers. 31 According to 12-week phase II trials, the endometrial thickness, assessed by a transvaginal ultrasound, remained relatively unchanged. 31, 32 In a phase III trial of postmenopausal women, with a treatment period of 12 weeks, taking either ospemifene-30 mg or 60 mg-or placebo, there was minimal change in the endometrial thickness, and their endometrial biopsy showed no cases of endometrial hyperplasia or carcinoma. 21 Extension studies demonstrated no significant endometrial changes associated with the use of ospemifene for at least up to 1 year of treatment. 12, 22, 24 The FDA concluded that ospemifene 60 mg per day was generally safe. However, the safety profile was based on a study with a treatment period of 52 weeks; as such, the safety of longer usage is uncertain. months. 34 These studies suggest that ospemifene does not have an adverse effect on lipid profiles.
Side Effects
Hot flashes were the most frequently reported side effects of ospemifene, with reported occurrence of 2% in the placebo group and 7.2% in the ospemifene group; however, it was not severe enough to lead to discontinuation. 21, 25 The incidence rates of thromboembolic and hemorrhagic stroke were 0.72 and 1.45 per 1,000 women, respectively, in the ospemifene group and 1.04 and 0 per 1,000 women, respectively, in the placebo group. The incidence of deep vein thrombosis was 1.45 per 1,000 women in the ospemifene group and 1.04 per 1,000 women in the placebo group. 35 Ospemifene is con-
Drug Interactions
Concomitant use of estrogens, as well as estrogen agonists/antagonists, is prohibited. To date, in vivo experiments demonstrated that the metabolism of ospemifene was induced by rifampin and was inhibited by ketoconazole or fluconazole. Therefore, rifampin, ketoconazole and fluconazole
should not be prescribed to women taking ospemifene. 36 Coadministration of ospemifene with drugs that inhibit CYP450 3A4 (CYP3A4) and CYP450 2C9 (CYP2C9) may also increase the risk of adverse reactions.
Conclusion
Ospemifene is the first SERM approved to treat dyspareunia associated with VVA. Ospemifene has been shown to reverse the structural changes associated with VVA and relieve symptoms of dyspareunia. Ospemifene is generally safe, showing minimal impact on breast cancer or endometrial hyperplasia/carcinoma. Further studies are needed to evaluate its long-term efficacy and safety.
